Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

Possible safety signals for transverse myelitis — spinal cord inflammation — after viral-vector vaccines were identified in ...

and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its ...

"The Chinese poultry lineage may have experienced more vaccine-driven selection compared to other lineages," the researchers wrote.

or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that ...

Suresh Mittal, Distinguished Professor of Virology in the College of Veterinary Medicine, presented “Universal Influenza Vaccine — An Aspiration or Reality?” at the Westwood Lecture Series on Jan. 28.

When a person is infected with one of these pathogens, their droplets contain the virus and enter other people’s bodies via the nose and mouth. It might seem to make sense to tailor a vaccine ...

Viral protein is made intracellularly and the protein is processed via the endogenous MHC class I pathway. DNA vaccines. DNA vaccines favor a cell-mediated immune response. DNA plasmid vector ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today highlighted that it is committed to playing a pivotal role in reinforcing ...

--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5 ... uses a proprietary PIV5 vector, which is not known to ...